proteasome inhibitor

Also found in: Wikipedia.

pro·te·a·some in·hi·bi·tor

(prō'tē-ă-sōm in-hib'i-tŏr)
Medication to treat multiple myeloma by blocking proteasomes to disrupt growth.
References in periodicals archive ?
The breadth and depth of the TOURMALINE program allows us to gather important data across a broad range of patients that live with multiple myeloma and to expand on the efficacy and safety profile of our oral proteasome inhibitor, ixazomib.
We are excited to offer patients the first oral proteasome inhibitor as an alternative treatment option for those with multiple myeloma," said Gary Kadlec, president of Diplomat.
The multi-center study with MLN9708, an investigational, oral proteasome inhibitor, will be conducted in Europe and North America.
In July 2012, the market reached a new milestone with the approval of Onyx's Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster.
Phase 1 trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
Velcade, developed by Millennium Pharmaceuticals that was acquired by Takeda, was the first proteasome inhibitor approved.
Building upon early stage microbial discoveries by researchers at the University of California, San Diego's Scripps Institution of Oceanography, Nereus is developing a novel and highly selective tumour vascular disrupting agent (VDA; NPI-2358) derived from a marine fungus and a potent second generation proteasome inhibitor (NPI-0052) isolated from a novel marine bacteria.
VELCADE (bortezomib) for Injection, the market leader for multiple myeloma and mantle cell lymphoma patients, who have received at least one prior therapy, is the first and only marketed proteasome inhibitor.
To demonstrate that this peptide bond hydrolysis was actually catalyzed by circulating proteasomes, we repeated the assay in the presence of the proteasome inhibitor lactacystin and found that at a concentration of 1 [micro]mol/L lactacystin inhibited the activity almost quantitatively.
Last year, the Food and Drug Administration approved the proteasome inhibitor bortezomib (Velcade) for the treatment of multiple myeloma, a cancer of the blood.
Cells treatments were: vehicle only (control); proteasome inhibitor (MG132); calpain inhibitor (ALLN) and estrogen for 24 hrs.
The FDA decision follows the recent approval of KYPROLIS([R]), a second-generation proteasome inhibitor for myeloma patients who have relapsed after previous therapies.

Full browser ?